spacer
home > ebr > autumn 2018 > determining peptides
PUBLICATIONS
European Biopharmaceutical Review

Determining Peptides

Therapeutic peptides are often applied via the following routes: intramuscular (IM), intraperitoneal (IP), intravenous (IV), or inhalative. Only a few peptides are stable in the stomach (acidic plus pepsin digestion) and the intestine (trypsin digestion) after oral application. Determination in plasma is very complex, as far as selectivity is concerned, because millions of endogenous peptides and proteins can be found in plasma.

Usually, the determination of a drug in plasma starts with some questions:

• How much of that drug is applied per kg body weight
• Which route of application is used (IM, IP, IV, oral, or inhalative)
• Is anything known about the first pass effect (leading to metabolites and, therefore, lowering the parent drug concentration)
• Does the molecule show a high volume of bodily distribution (which often means that the molecule shows very lipophilic characteristics or high tissue attraction and, therefore, a fast elimination half-life and low concentration levels in plasma

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Hermann Mascher, bioanalytical consultant and founder of pharm-analyt Labor, has more than 100 publications in peer reviewed journals (with more than a 230 impact factor). Hermann is the inventor of three patents for biomarkers in the area of rare lysosomal storage diseases and has developed analytical methods for dozens of peptides.
spacer
Professor Hermann Mascher
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Organization Updates

Philadelphia, PA – May 20, 2019 – PCI Pharma Services, a leading biopharmaceutical outsourcing services provider, is pleased to announce the following management updates to help drive the company’s future vision, strategy and growth.
More info >>

White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement